SP0133 ANCA and their environment

SP0133 ANCA and their environment

Bibliografski detalji
Glavni autor:	Luqmani, R
Format:	Conference item
Izdano:	BMJ Publishing Group 2017

Slični predmeti

Maintenance of clinical remission in ANCA-associated vasculitis.
od: Luqmani, R
Izdano: (2013)

Towards diagnostic criteria for the ANCA-associated vasculitides.
od: Luqmani, R
Izdano: (2007)

Damage assessment in ANCA-associated vasculitis.
od: Bhamra, K, i dr.
Izdano: (2012)

ANCA POSITIVE AND ANCA NEGATIVE MICROSCOPIC POLYARTERITIS
od: Adu, D, i dr.
Izdano: (1994)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
od: Luqmani, R
Izdano: (2013)

Outcome measures in ANCA-associated vasculitis.
od: Suppiah, R, i dr.
Izdano: (2010)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
od: Arnold, D, i dr.
Izdano: (2010)

ANCA-associated vasculitis: Where can we go from here?
od: Luqmani, R
Izdano: (2010)

Cutaneous manifestations of ANCA-associated vasculitis
od: Chiesafuxench, Z, i dr.
Izdano: (2016)

Cardiovascular outcomes in ANCA associated vasculitis
od: Mukhtyar, C, i dr.
Izdano: (2008)

Diagnosis and management of ANCA associated vasculitis.
od: Berden, A, i dr.
Izdano: (2012)

The prognostic value of BVAS and VDI in ANCA-AAV
od: Suppiah, R, i dr.
Izdano: (2011)

Classification criteria for the anca-associated vasculitides
od: Robson, J, i dr.
Izdano: (2019)

DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
od: McLaren, J, i dr.
Izdano: (2003)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
od: McLaren, J, i dr.
Izdano: (2001)

P01.33. A new development of Triterpene Acids-containing extracts from Viscum album L. displays synergistic induction of apoptosis in childhood leukemia
od: Delebinski C, i dr.
Izdano: (2012-06-01)

Global ethnic and geographic idfferences in the clinical features of ANCA-associated vasculitis
od: Pearce, F, i dr.
Izdano: (2016)

Predicting cardiovascular events in patients with newly diagnosed ANCA-AAV
od: Suppiah, R, i dr.
Izdano: (2011)

Predictors of renal involvement in ANCA associated vasculitis
od: Kronbichler, A, i dr.
Izdano: (2018)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
od: Luqmani, R, i dr.
Izdano: (2007)

Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis.
od: Luqmani, R, i dr.
Izdano: (2002)

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.
od: McLaren, J, i dr.
Izdano: (2000)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
od: Luqmani, R, i dr.
Izdano: (1999)

Explaining fatigue in ANCA-associated vasculitis.
od: Basu, N, i dr.
Izdano: (2013)

Explaining fatigue in ANCA-associated vasculitis
od: Basu, N, i dr.
Izdano: (2013)

Cutaneous manifestations of ANCA-associated vasculitis are common, varied, and associated with systemic disease
od: Micheletti, R, i dr.
Izdano: (2017)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
od: Salisbury, E, i dr.
Izdano: (2003)

Long-term survival of ANCA-associated vasculitis
od: Flossmann, O, i dr.
Izdano: (2009)

Markers for work disability in ANCA-associated vasculitis
od: Basu, N, i dr.
Izdano: (2013)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
od: Salisbury, E, i dr.
Izdano: (2003)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
od: Salisbury, E, i dr.
Izdano: (2004)

Comparison of disease activity measures for ANCA-associated vasculitis.
od: Merkel, P, i dr.
Izdano: (2004)

DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE
od: McLaren, J, i dr.
Izdano: (2004)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
od: Jones, R, i dr.
Izdano: (2010)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
od: Salisbury, E, i dr.
Izdano: (2003)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
od: Ntatsaki, E, i dr.
Izdano: (2014)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
od: Lapraik, C, i dr.
Izdano: (2007)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
od: Zachary S. Wallace, i dr.
Izdano: (2019-12-01)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
od: Basu, N, i dr.
Izdano: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
od: Basu, N, i dr.
Izdano: (2014)